دورية أكاديمية

Impact of post-transplant cyclophosphamide (PTCy)-based prophylaxis in matched sibling donor allogeneic haematopoietic cell transplantation for patients with myelodysplastic syndrome:a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT

التفاصيل البيبلوغرافية
العنوان: Impact of post-transplant cyclophosphamide (PTCy)-based prophylaxis in matched sibling donor allogeneic haematopoietic cell transplantation for patients with myelodysplastic syndrome:a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT
المؤلفون: Salas, María Queralt, Eikema, Diderik Jan, Koster, Linda, Maertens, Johan, Passweg, Jakob, Finke, Jürgen, Broers, Annoek E.C., Koc, Yener, Kröger, Nicolaus, Ozkurt, Zubeyde Nur, Pascual-Cascon, María Jesús, Platzbecker, Uwe, Van Gorkom, Gwendolyn, Schroeder, Thomas, López-Lorenzo, José Luis, Martino, Massimo, Chiusolo, Patrizia, Kaufmann, Martin, Onida, Francesco, Gurnari, Carmelo, Scheid, Christof, Drozd-Sokolowska, Joanna, Raj, Kavita, Robin, Marie, McLornan, Donal P.
المصدر: Salas , M Q , Eikema , D J , Koster , L , Maertens , J , Passweg , J , Finke , J , Broers , A E C , Koc , Y , Kröger , N , Ozkurt , Z N , Pascual-Cascon , M J , Platzbecker , U , Van Gorkom , G , Schroeder , T , López-Lorenzo , J L , Martino , M , Chiusolo , P , Kaufmann , M , Onida , F , Gurnari , C , Scheid , C , Drozd-Sokolowska , J , Raj , K ....
سنة النشر: 2024
المجموعة: Maastricht University Research Publications
الوصف: We retrospectively compared outcomes of 404 MDS patients undergoing 1st matched sibling donor allo-HCT receiving either PTCy-based (n = 66) or other "conventional prophylaxis" (n = 338; mostly calcineurin inhibitor + methotrexate or MMF). Baseline characteristics were balanced, except for higher use of myeloablative regimens in the PTCy group (52.3% vs. 38.2%, p = 0.047). Incidences of neutrophil (Day +28: 89% vs. 97%, p = 0.011) and platelet (Day +100: 89% vs. 97%, p < 0.001) engraftment were lower for PTCy-based. Day +100 cumulative incidences of grade II-IV and III-IV aGVHD, and 5-year CI of extensive cGVHD were 32%, 18% and 18% for PTCy-based and 25% (p = 0.3), 13% (p = 0.4) and 31% (p = 0.09) for the conventional cohort. Five-year OS (51% vs. 52%, p = 0.6) and GRFS (33% vs. 25%, p = 0.6) were similar between groups. Patients receiving PTCy had a trend to a lower cumulative incidence of relapse (20% vs. 33%, p = 0.06), not confirmed on multivariable analysis (p = 0.3). Although higher NRM rates were observed in patients receiving PTCy (32% vs. 21%, p = 0.02) on univariate analysis, this was not confirmed on multivariate analysis (HR 1.46, p = 0.18), and there was no resultant effect on OS (HR 1.20, p = 0.5). Based on these data, PTCy prophylaxis appears to be an attractive option for patients with MDS undergoing MSD allo-HCT.
نوع الوثيقة: article in journal/newspaper
اللغة: English
العلاقة: https://cris.maastrichtuniversity.nl/en/publications/9f4c7e71-aa0c-496c-8de5-5cbf3d695eb6Test
DOI: 10.1038/s41409-023-02159-1
الإتاحة: https://doi.org/10.1038/s41409-023-02159-1Test
https://cris.maastrichtuniversity.nl/en/publications/9f4c7e71-aa0c-496c-8de5-5cbf3d695eb6Test
حقوق: info:eu-repo/semantics/openAccess
رقم الانضمام: edsbas.67D125A9
قاعدة البيانات: BASE